DK2038294T3 - 18-methyl-19-nor-androst-4-en-17,17-spiroether (18-methyl-19-nor-20-spirox-4-en-3-oner) og farmaceutiske præparater, der indeholder disse - Google Patents

18-methyl-19-nor-androst-4-en-17,17-spiroether (18-methyl-19-nor-20-spirox-4-en-3-oner) og farmaceutiske præparater, der indeholder disse

Info

Publication number: DK2038294T3
Authority: DK; Denmark
Prior art keywords: ene; methyl; spirox; androst; pharmaceutical compositions
Prior art date: 2006-06-29

Application number

DK07765033.1T

Other languages

English (en)

Inventor

Frederik Menges

Jan Huebner

Rolf Bohlmann

Joachim Kuhnke

Norbert Gallus

Steffen Borden

Hans-Peter Muhn

Katja Prelle

Original Assignee

Bayer Schering Pharma Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2006-06-29

Filing date

2007-06-29

Publication date

2011-03-28

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38626491&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK2038294(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2007-06-29 Application filed by Bayer Schering Pharma Ag filed Critical Bayer Schering Pharma Ag

2011-03-28 Application granted granted Critical

2011-03-28 Publication of DK2038294T3 publication Critical patent/DK2038294T3/da

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J53/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by condensation with a carbocyclic rings or by formation of an additional ring by means of a direct link between two ring carbon atoms, including carboxyclic rings fused to the cyclopenta(a)hydrophenanthrene skeleton are included in this class
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J53/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by condensation with a carbocyclic rings or by formation of an additional ring by means of a direct link between two ring carbon atoms, including carboxyclic rings fused to the cyclopenta(a)hydrophenanthrene skeleton are included in this class
- C07J53/002—Carbocyclic rings fused
- C07J53/004—3 membered carbocyclic rings
- C07J53/008—3 membered carbocyclic rings in position 15/16
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/34—Gestagens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/42—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of mineralocorticosteroids

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Endocrinology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Diabetes (AREA)
Reproductive Health (AREA)
Gynecology & Obstetrics (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Steroid Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Cosmetics (AREA)

DK07765033.1T 2006-06-29 2007-06-29 18-methyl-19-nor-androst-4-en-17,17-spiroether (18-methyl-19-nor-20-spirox-4-en-3-oner) og farmaceutiske præparater, der indeholder disse DK2038294T3 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
DE102006030416A DE102006030416A1 (de)	2006-06-29	2006-06-29	18-Methyl-19-nor-androst-4-en-17,17-spiroether (18-Methyl-19-nor-20-spirox-4-en-3-one) sowie diese enthaltende pharmazeutische Präparate
PCT/EP2007/005893 WO2008000521A1 (de)	2006-06-29	2007-06-29	18-methyl-19-nor-androst-4-en-17,17-spiroether (18-methyl-19-nor-20- spirox-4-en-3-one), sowie diese enthaltende pharmazeutische präparate

Publications (1)

Publication Number	Publication Date
DK2038294T3 true DK2038294T3 (da)	2011-03-28

Family

ID=38626491

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK07765033.1T DK2038294T3 (da)	2006-06-29	2007-06-29	18-methyl-19-nor-androst-4-en-17,17-spiroether (18-methyl-19-nor-20-spirox-4-en-3-oner) og farmaceutiske præparater, der indeholder disse

Country Status (40)

Country	Link
US (1)	US7846917B2 (da)
EP (1)	EP2038294B1 (da)
JP (1)	JP5326085B2 (da)
KR (1)	KR101440640B1 (da)
CN (1)	CN101511857B (da)
AR (1)	AR061736A1 (da)
AT (1)	ATE490967T1 (da)
AU (1)	AU2007263944B2 (da)
BR (1)	BRPI0713934A2 (da)
CA (1)	CA2656443C (da)
CL (1)	CL2007001919A1 (da)
CO (1)	CO6150134A2 (da)
CR (1)	CR10548A (da)
CY (1)	CY1111658T1 (da)
DE (2)	DE102006030416A1 (da)
DK (1)	DK2038294T3 (da)
DO (1)	DOP2008000089A (da)
EC (1)	ECSP089014A (da)
ES (1)	ES2357698T3 (da)
GT (1)	GT200800307A (da)
HN (1)	HN2008001934A (da)
HR (1)	HRP20110161T1 (da)
IL (1)	IL195935A0 (da)
MA (1)	MA30596B1 (da)
MX (1)	MX2009000082A (da)
MY (1)	MY155015A (da)
NO (1)	NO20090459L (da)
NZ (1)	NZ573951A (da)
PE (1)	PE20080995A1 (da)
PL (1)	PL2038294T3 (da)
PT (1)	PT2038294E (da)
RS (1)	RS51722B (da)
RU (1)	RU2440365C2 (da)
SI (1)	SI2038294T1 (da)
TN (1)	TNSN08518A1 (da)
TW (1)	TWI413645B (da)
UA (1)	UA94952C2 (da)
UY (1)	UY30451A1 (da)
WO (1)	WO2008000521A1 (da)
ZA (1)	ZA200900673B (da)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE102007063498A1 (de) *	2007-12-29	2009-07-02	Bayer Schering Pharma Aktiengesellschaft	15,16-Methylen-steroid-17,17-Lactol-Derivat, dessen Verwendung und das Derivat enthaltende Arzneimittel
DE102007063496A1 (de)	2007-12-29	2009-07-02	Bayer Schering Pharma Aktiengesellschaft	15,16-Methylen-17-(1'-propenyl)-17-3'-oxidoestra-4-en-3-on-Derivat, dessen Verwendung und das Derivat enthaltende Arzneimittel
DE102008026793A1 (de)	2008-06-02	2009-12-03	Bayer Schering Pharma Aktiengesellschaft	C-Ring-substituierte Pregn-4-en-21,17-carbolactone, sowie diese enthaltende pharmazeutische Präparate
WO2010066354A1 (de) *	2008-12-12	2010-06-17	Bayer Schering Pharma Aktiengesellschaft	VERWENDUNG VON 17β-CYANO-18A-HOMO-19-NOR-ANDROST-4-EN-DERIVATEN ZUR HERSTELLUNG EINES ARZNEIMITTELS IN DEPOT-FORM ZUR PARENTERALEN ANWENDUNG SOWIE DEPOT-ARZNEIMITTEL ENTHALTEND 17β-CYANO-18A-HOMO-19-NOR-ANDROST-4-EN-DERIVATE ZUR PARENTERALEN ANWENDUNG
WO2012059594A1 (en)	2010-11-04	2012-05-10	Bayer Pharma Aktiengesellschaft	Mineralcorticoid receptor antagonists for the treatment of corticoid-induced obesity
TW201350122A (zh) *	2012-04-23	2013-12-16	Bayer Pharma AG	１８－甲基－１５β，１６β－亞甲基－１９－降－２０－螺氧－４－烯－３－酮的子宮內用途，包含１８－甲基－１５β，１６β－亞甲基－１９－降－２０－螺氧－４－烯－３－酮的子宮內系統，及其於避孕及婦科治療之用途
EP2841073A1 (de) *	2012-04-23	2015-03-04	Bayer Pharma Aktiengesellschaft	ANWENDUNG VON 18-METHYL-15ß,16ß-METHYLEN-19-NOR-20-SPIROX-4-EN-3-ONEN BEI DER THERAPIE DER MENORRHAGIA, SOWIE 18-METHYL-15ß,16ß-METHYLEN-19-NOR-20-SPIROX-4-EN-3-ONE ENTHALTENDE INTRAUTERINE SYSTEME FÜR DIE THERAPIE UTERINEN BLUTUNGSSTÖRUNGEN
WO2015055789A1 (en) *	2013-10-17	2015-04-23	Bayer Pharma Aktiengesellschaft	INTRAVAGINAL USE OF 18-METHYL-15ß,16ß-METHYLENE-19-NOR-20-SPIROX-4-EN-3-ONES, INTRAVAGINAL RINGS COMPRISING 18-METHYL-15ß,16ß-METHYLENE-19-NOR-20-SPIROX-4-EN-3-ONES, AND USE THEREOF IN CONTRACEPTION
JP2016539088A (ja) *	2013-10-18	2016-12-15	バイエル・オサケユキテュアＢａｙｅｒＯｙ	子宮内送達システム
CN105237605B (zh) *	2014-07-11	2019-01-25	上海迪赛诺生物医药有限公司	一种用于合成孕二烯酮的中间体及其制备方法和应用
CN109575094B (zh) *	2019-01-17	2021-01-26	浙江仙琚制药股份有限公司	替勃龙中间体的制备方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3798213A (en) *	1971-01-25	1974-03-19	Merck & Co Inc	7 alpha-methyl-20-spiroxane-3-ones and process
DE3022337A1 (de) *	1980-06-11	1982-01-07	Schering Ag Berlin Und Bergkamen, 1000 Berlin	Praeparate zur kontrazeption und zur behandlung gynaekologischer stoerungen
DE3111950A1 (de)	1981-03-23	1982-09-30	Schering Ag, 1000 Berlin Und 4619 Bergkamen	7(alpha)-alkoxycarbonyl-15(beta).16(beta)-methylen-4-androsten-3-one, verfahren zu ihrer herstellung und verwendung als arzneimittel
DE3402329A1 (de) *	1984-01-20	1985-08-01	Schering AG, 1000 Berlin und 4709 Bergkamen	6,6-ethylen-15,16-methylen-3-oxo-17(alpha)-pregn-4-en-21,17-carbolactone, verfahren zu deren herstellung und diese enthaltende pharmazeutische praeparate
DE19651000A1 (de) *	1996-12-01	1998-06-04	Schering Ag	Oxyiminopregnancarbolactone
EP1223174A3 (en)	1996-12-11	2005-03-16	G.D. Searle & Co.	Processes for preparation of 3-keto-7alpha-alkoxycarbonyl-delta-4,5- steroids and intermediates useful therein
US6787531B1 (en) *	1999-08-31	2004-09-07	Schering Ag	Pharmaceutical composition for use as a contraceptive
US8445469B2 (en) *	2004-12-30	2013-05-21	Bayer Intellectual Property Gmbh	18-methyl-19-nor-17-pregn-4-ene-21,17-carbolactones, as well as pharmaceutical preparations that contain the latter
DE102004063864A1 (de) *	2004-12-30	2006-07-13	Schering Ag	18-Methyl-19-nor-17-pregn-4-en21,17-carbolactone, sowie diese enthaltende pharmazeutische Präparate

2006
- 2006-06-29 DE DE102006030416A patent/DE102006030416A1/de not_active Withdrawn
2007
- 2007-06-28 US US11/769,952 patent/US7846917B2/en not_active Expired - Fee Related
- 2007-06-29 AR ARP070102908A patent/AR061736A1/es not_active Application Discontinuation
- 2007-06-29 HR HR20110161T patent/HRP20110161T1/hr unknown
- 2007-06-29 JP JP2009517034A patent/JP5326085B2/ja not_active Expired - Fee Related
- 2007-06-29 DE DE502007005902T patent/DE502007005902D1/de active Active
- 2007-06-29 AU AU2007263944A patent/AU2007263944B2/en not_active Ceased
- 2007-06-29 MY MYPI20071041A patent/MY155015A/en unknown
- 2007-06-29 DK DK07765033.1T patent/DK2038294T3/da active
- 2007-06-29 UY UY30451A patent/UY30451A1/es not_active Application Discontinuation
- 2007-06-29 EP EP07765033A patent/EP2038294B1/de active Active
- 2007-06-29 KR KR1020087031791A patent/KR101440640B1/ko not_active Expired - Fee Related
- 2007-06-29 MX MX2009000082A patent/MX2009000082A/es active IP Right Grant
- 2007-06-29 ES ES07765033T patent/ES2357698T3/es active Active
- 2007-06-29 CL CL200701919A patent/CL2007001919A1/es unknown
- 2007-06-29 RU RU2009102772/04A patent/RU2440365C2/ru not_active IP Right Cessation
- 2007-06-29 BR BRPI0713934-9A patent/BRPI0713934A2/pt not_active IP Right Cessation
- 2007-06-29 NZ NZ573951A patent/NZ573951A/en not_active IP Right Cessation
- 2007-06-29 SI SI200730533T patent/SI2038294T1/sl unknown
- 2007-06-29 CN CN2007800246245A patent/CN101511857B/zh not_active Expired - Fee Related
- 2007-06-29 WO PCT/EP2007/005893 patent/WO2008000521A1/de not_active Ceased
- 2007-06-29 RS RS20110109A patent/RS51722B/sr unknown
- 2007-06-29 TW TW096123940A patent/TWI413645B/zh not_active IP Right Cessation
- 2007-06-29 PT PT07765033T patent/PT2038294E/pt unknown
- 2007-06-29 CA CA2656443A patent/CA2656443C/en not_active Expired - Fee Related
- 2007-06-29 PL PL07765033T patent/PL2038294T3/pl unknown
- 2007-06-29 UA UAA200900433A patent/UA94952C2/uk unknown
- 2007-06-29 AT AT07765033T patent/ATE490967T1/de active
- 2007-07-02 PE PE2007000837A patent/PE20080995A1/es not_active Application Discontinuation
2008
- 2008-12-15 IL IL195935A patent/IL195935A0/en not_active IP Right Cessation
- 2008-12-15 TN TNP2008000518A patent/TNSN08518A1/en unknown
- 2008-12-26 CO CO08137168A patent/CO6150134A2/es unknown
- 2008-12-29 HN HN2008001934A patent/HN2008001934A/es unknown
- 2008-12-29 EC EC2008009014A patent/ECSP089014A/es unknown
- 2008-12-29 DO DO2008000089A patent/DOP2008000089A/es unknown
2009
- 2009-01-05 CR CR10548A patent/CR10548A/es unknown
- 2009-01-22 MA MA31582A patent/MA30596B1/fr unknown
- 2009-01-28 NO NO20090459A patent/NO20090459L/no not_active Application Discontinuation
- 2009-01-28 ZA ZA200900673A patent/ZA200900673B/xx unknown
- 2009-03-05 GT GT200800307A patent/GT200800307A/es unknown
2011
- 2011-03-08 CY CY20111100261T patent/CY1111658T1/el unknown

Also Published As

Publication number	Publication date
KR101440640B1 (ko)	2014-09-22
CL2007001919A1 (es)	2008-05-16
JP2009541405A (ja)	2009-11-26
HRP20110161T1 (hr)	2011-04-30
MA30596B1 (fr)	2009-07-01
WO2008000521A1 (de)	2008-01-03
PT2038294E (pt)	2011-03-14
UY30451A1 (es)	2008-01-31
PL2038294T3 (pl)	2011-05-31
CN101511857A (zh)	2009-08-19
RS51722B (sr)	2011-10-31
EP2038294B1 (de)	2010-12-08
ECSP089014A (es)	2009-01-30
PE20080995A1 (es)	2008-10-03
MY155015A (en)	2015-08-28
AU2007263944A1 (en)	2008-01-03
ZA200900673B (en)	2010-04-28
CA2656443C (en)	2014-10-07
DE502007005902D1 (de)	2011-01-20
ES2357698T3 (es)	2011-04-28
CA2656443A1 (en)	2008-01-03
DE102006030416A1 (de)	2008-01-03
TNSN08518A1 (en)	2010-04-14
AR061736A1 (es)	2008-09-17
CO6150134A2 (es)	2010-04-20
TWI413645B (zh)	2013-11-01
NO20090459L (no)	2009-03-10
ATE490967T1 (de)	2010-12-15
US7846917B2 (en)	2010-12-07
CY1111658T1 (el)	2015-10-07
KR20090021294A (ko)	2009-03-02
US20080153787A1 (en)	2008-06-26
IL195935A0 (en)	2009-09-01
HN2008001934A (es)	2012-01-17
TW200811193A (en)	2008-03-01
EP2038294A1 (de)	2009-03-25
AU2007263944B2 (en)	2013-07-18
GT200800307A (es)	2009-11-03
MX2009000082A (es)	2009-01-23
HK1133659A1 (en)	2010-04-01
NZ573951A (en)	2011-06-30
JP5326085B2 (ja)	2013-10-30
RU2009102772A (ru)	2010-08-10
UA94952C2 (uk)	2011-06-25
CN101511857B (zh)	2012-10-31
RU2440365C2 (ru)	2012-01-20
DOP2008000089A (es)	2009-02-15
BRPI0713934A2 (pt)	2012-12-04
SI2038294T1 (sl)	2011-04-29
CR10548A (es)	2009-01-27

Publication	Publication Date	Title
DK2038294T3 (da)	2011-03-28	18-methyl-19-nor-androst-4-en-17,17-spiroether (18-methyl-19-nor-20-spirox-4-en-3-oner) og farmaceutiske præparater, der indeholder disse
DK2069352T3 (da)	2013-12-02	Bestemte kemiske enheder, sammensætninger og fremgangsmåder
DK2010501T3 (da)	2014-06-30	Imidazolbaserede forbindelser, sammensætninger omfattende disse og fremgangsmåder for deres anvendelse
DK2114924T3 (da)	2012-04-10	Co-krystaller og farmaceutiske sammensætninger omfattende disse
DK1884242T3 (da)	2013-05-06	Farmaceutisk sammensætning omfattende lurasidon
ITBO20050123A1 (it)	2005-06-06	Formulazioni farmaceutiche gastroresistenti contenenti rifaximina
DK2209375T3 (da)	2014-10-06	Parp-inhibitorforbindelser, præparater og fremgangsmåder til anvendelse deraf
BRPI0511900A (pt)	2008-01-22	composições farmacêuticas
NO343748B1 (no)	2019-05-27	Cyklopaminanaloger og farmasøytiske preparater omfattende slike
BRPI0719393A2 (pt)	2015-03-31	Composição farmacêutica
DK2207773T3 (da)	2012-09-10	Heterocyklisk forbindelse og farmaceutisk sammensætning deraf.
DK2036892T3 (da)	2010-06-07	1,2,4,5-tetrahydro-3H-benzazepinforbindelser, fremgangsmåde til fremstilling heraf og farmaceutiske sammensætninger indeholdende disse
DK1845978T3 (da)	2010-12-13	Substituerede pyrazolopyridiner, sammensætninger, som indeholder disse, fremgangsmåde til fremstilling heraf, og anvendelse heraf
NO20075628L (no)	2007-11-05	Farmasøytiske formuleringer
DK2076260T3 (da)	2011-06-27	N-methylaminomethyl-isoindol-forbindelser og sammensætninger, der indeholder disse, samt fremgangsmåder til deres anvendelse
DK2966175T3 (da)	2019-07-01	Farmaceutiske sammensætninger indeholdende cortexolon-17-alpha-propionat
BRPI0716445A2 (pt)	2013-09-17	composiÇço farmacÊutica
BRPI0720234A2 (pt)	2013-12-24	Composição farmacêutica
DK2254873T3 (da)	2014-06-30	Benzodiazepinforbindelse og farmaceutisk sammensætning.
EP2047257A4 (en)	2011-11-16	NEW CELLULAR GLYCAN COMPOSITIONS
DK2107055T3 (da)	2011-06-27	Dosmetinderivater, fremgangsmåde til fremstilling heraf og farmaceutiske sammensætninger indeholdende disse
NO20091520L (no)	2009-07-24	Skummende blandinger og fremgangsmåter for fremstilling av disse
BRPI0810399A2 (pt)	2014-11-04	Composto, composição farmacêutica que o contém e uso do mesmo
IL218745A0 (en)	2012-05-31	Pharmaceutical compositions containing roflumilast
DK3072507T3 (da)	2021-02-08	Farmaceutiske sammensætninger til glukokortikoidsubstitutionsterapi